CA3025756A1 - Prl3 antibody - Google Patents
Prl3 antibody Download PDFInfo
- Publication number
- CA3025756A1 CA3025756A1 CA3025756A CA3025756A CA3025756A1 CA 3025756 A1 CA3025756 A1 CA 3025756A1 CA 3025756 A CA3025756 A CA 3025756A CA 3025756 A CA3025756 A CA 3025756A CA 3025756 A1 CA3025756 A1 CA 3025756A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- prl
- prl3
- antibody
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201604834P | 2016-06-14 | ||
| SG10201604834P | 2016-06-14 | ||
| PCT/SG2017/050300 WO2017217934A1 (en) | 2016-06-14 | 2017-06-14 | Prl3 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3025756A1 true CA3025756A1 (en) | 2017-12-21 |
Family
ID=60663634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3025756A Pending CA3025756A1 (en) | 2016-06-14 | 2017-06-14 | Prl3 antibody |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11155636B2 (https=) |
| EP (1) | EP3469003A4 (https=) |
| JP (2) | JP2019531254A (https=) |
| KR (1) | KR102451588B1 (https=) |
| CN (1) | CN109476759B (https=) |
| AU (1) | AU2017285995B2 (https=) |
| BR (1) | BR112018075901A2 (https=) |
| CA (1) | CA3025756A1 (https=) |
| SG (1) | SG11201811068YA (https=) |
| WO (1) | WO2017217934A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023219091A1 (ja) | 2022-05-11 | 2023-11-16 | 国立研究開発法人産業技術総合研究所 | アンモニア分離膜及びそれを用いたアンモニア分離方法 |
| TW202532435A (zh) * | 2023-11-30 | 2025-08-16 | 新加坡科技研究局 | 治療新生血管性眼疾之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287644A1 (en) * | 2004-05-14 | 2005-12-29 | Genesis Biotech Inc. | Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas |
| US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| EP1848742A1 (en) * | 2005-01-28 | 2007-10-31 | Attogen, Inc. | Anti-prl-3 antibodies and methods of use thereof |
| JP2010530735A (ja) * | 2007-05-03 | 2010-09-16 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体 |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| EP2506864B1 (en) * | 2009-11-30 | 2016-07-27 | Agency For Science, Technology And Research | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| JP6343017B2 (ja) * | 2014-02-07 | 2018-06-13 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 癌の予後診断のためのバイオマーカーおよび療法のためのターゲットとしてのｐｒｌ−３ |
-
2017
- 2017-06-14 SG SG11201811068YA patent/SG11201811068YA/en unknown
- 2017-06-14 AU AU2017285995A patent/AU2017285995B2/en active Active
- 2017-06-14 CN CN201780037479.8A patent/CN109476759B/zh active Active
- 2017-06-14 EP EP17813707.1A patent/EP3469003A4/en active Pending
- 2017-06-14 JP JP2018565319A patent/JP2019531254A/ja active Pending
- 2017-06-14 WO PCT/SG2017/050300 patent/WO2017217934A1/en not_active Ceased
- 2017-06-14 CA CA3025756A patent/CA3025756A1/en active Pending
- 2017-06-14 KR KR1020197001195A patent/KR102451588B1/ko active Active
- 2017-06-14 US US16/309,439 patent/US11155636B2/en active Active
- 2017-06-14 BR BR112018075901-5A patent/BR112018075901A2/pt unknown
-
2022
- 2022-03-04 JP JP2022033194A patent/JP7408707B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3469003A4 (en) | 2020-07-29 |
| US20200181283A1 (en) | 2020-06-11 |
| AU2017285995A1 (en) | 2019-01-31 |
| CN109476759A (zh) | 2019-03-15 |
| EP3469003A1 (en) | 2019-04-17 |
| JP2019531254A (ja) | 2019-10-31 |
| BR112018075901A2 (pt) | 2019-03-19 |
| CN109476759B (zh) | 2022-11-08 |
| JP7408707B2 (ja) | 2024-01-05 |
| AU2017285995B2 (en) | 2023-11-30 |
| KR20190024961A (ko) | 2019-03-08 |
| SG11201811068YA (en) | 2019-01-30 |
| KR102451588B1 (ko) | 2022-10-06 |
| JP2022078202A (ja) | 2022-05-24 |
| WO2017217934A1 (en) | 2017-12-21 |
| US11155636B2 (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3027417C (en) | Anti-human trop-2 antibody having an antitumor activity in vivo | |
| AU2011255870B2 (en) | Anti-human TROP-2 antibody having antitumor activity in vivo | |
| JP7408707B2 (ja) | Ｐｒｌ３抗体 | |
| TW202342528A (zh) | 抗人類ｃｘｃｌ１抗體 | |
| HK40006061B (en) | Prl3 antibody | |
| HK40006061A (en) | Prl3 antibody | |
| NZ623464B2 (en) | Anti-human trop-2 antibody having an antitumor activity in vivo | |
| NZ716839B2 (en) | Anti-human trop-2 antibody having an antitumor activity in vivo | |
| NZ716839A (en) | Anti-human trop-2 antibody having an antitumor activity in vivo | |
| HK1198042B (en) | Anti-human trop-2 antibody exhibiting antitumor activity in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220329 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250102 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250509 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250509 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250509 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250829 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260202 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260202 |